PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys, It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABA<sub>A</sub> receptor, acting as a partial inverse agonist at the ñ<sub>5</sub> subtype and a weak partial agonist at the ñ<sub>3</sub> subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.